Objective. This study was performed to determine the efficacy and tolerability/safety of IQP-AE-103 on body weight reduction in\noverweight to moderately obese adults. Methods. A double-blind, randomized, placebo-controlled trial involved one hundred and\neight subjects (BMI between 25 and 35 kg/m^2) that were randomly assigned to either the low-dose or the high-dose IQP-AE-103\ngroup, or the placebo group. Following a 2-week run-in period, subjects received two capsules of investigational product after\nthree daily main meals for 12 weeks. Subjects were instructed to maintain a nutritionally balanced hypocaloric diet according to\nthe individualâ??s energy requirement. Body weight, body fat, and waist and hip circumference were measured at baseline, and after\n2, 4, 8, and 12 weeks. Subjects also rated their feelings of hunger and fullness using visual analogue scales, and food craving on a 5-\npoint scale at the same time intervals. Blood samplings for safety laboratory parameters were taken before and at the end of the\nstudy. Results. After 12 weeks of intake, the high-dose IQP-AE-103 group had a significantly greater weight loss compared with the\nplaceboâ?¦â?¦â?¦â?¦â?¦â?¦..
Loading....